

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM567018

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest in Intellectual Property at Reel/Frame No. 5923/0192		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cortland Capital Market Services LLC		03/12/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	SIGA Technologies, Inc.		
Street Address:	31 East 62nd Street		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10065		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Registration Number:	3729965	SIGA	
Registration Number:	3703521	SIGA	
Registration Number:	3723743	SIGA	
Registration Number:	3719987	SIGA	
Registration Number:	3703520	HUMAN BIOARMOR	
Registration Number:	3415362	ST-246	
Registration Number:	4597614	ARESTVYR	
Registration Number:	5046109	TPOXX	
CORRESPONDENCE DATA			
Fax Number:	2138918763		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	rhonda.deleon@lw.com		
Correspondent Name:	Latham & Watkins LLP		
Address Line 1:	355 South Grand Avenue		
Address Line 4:	Los Angeles, CALIFORNIA 90071-1560		
ATTORNEY DOCKET NUMBER:	052242-0010		
NAME OF SUBMITTER:	Rhonda DeLeon		

OP \$215.00 3729965

SIGNATURE:	/Rhonda DeLeon/
DATE SIGNED:	03/13/2020
Total Attachments: 6 source=SIGA - IP Release Executed#page1.tif source=SIGA - IP Release Executed#page2.tif source=SIGA - IP Release Executed#page3.tif source=SIGA - IP Release Executed#page4.tif source=SIGA - IP Release Executed#page5.tif source=SIGA - IP Release Executed#page6.tif	

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of March 12, 2020 ("Effective Date") by Cortland Capital Market Services LLC, a Delaware limited liability company, as administrative and collateral agent ("Agent"), in favor of SIGA Technologies, Inc., a Delaware corporation ("Grantor").

WHEREAS, pursuant to the terms and conditions of that certain Intellectual Property Security Agreement dated November 16, 2016, by Grantor in favor of Agent (the "IP Security Agreement"), Grantor granted to Agent a lien on and security interest in all of Grantor's right, title and interest in, to and under the Collateral (as defined in the IP Security Agreement), including, but not limited to, the patents, patent applications, and trademark registrations listed in Schedule 1 attached hereto;

WHEREAS, the IP Security Agreement was recorded with the United States Patent and Trademark Office on November 16, 2016 at Reel/Frame 5923/0192 with respect to trademarks, and at Reel/Frame 040349/0219 with respect to patents; and

WHEREAS, Grantor has paid all of its outstanding indebtedness to Agent.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent hereby terminates the IP Security Agreement, and hereby terminates, cancels and releases any and all security interests it has in, to and under the Collateral.

Agent represents and warrants that: (i) it has the full power and authority to execute this Release; (ii) it has not assigned, transferred, restricted or otherwise encumbered any security interest it has against the Collateral and; (iii) it has not recorded or otherwise evidenced its security interest with respect to the Collateral, other than those patents, patent applications, and trademarks set forth on Schedule 1, in any jurisdiction throughout the world.

Agent shall take all further actions, and provide to Grantor, its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments) requested by Grantor to more fully and effectively effectuate the purposes of this Release.

* * * * *

IN WITNESS WHEREOF, Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date.

**CORTLAND CAPITAL MARKET SERVICES,
LLC**

By: 

Name: Matthew Trybula
Title: Associate Counsel

SCHEDULE 1

Patents

Compound Series	Title/Description	Country	Application/ Patent No.	Status
Tecovirimat (ST-246, TPOXX) Family I	<i>COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES</i> Method of treatment, compounds, pharmaceutical composition, method of making	US	7,737,168	Issued
		US	8,124,643	Issued
		US	7,956,197	Issued
		US	7,687,641	Issued
		US	8,039,504	Issued
		US	8,530,509	Issued
		US	8,802,714	Issued
		US	9,045,418	Issued
Tecovirimat (ST-246, TPOXX) Family II	<i>POLYMORPHIC FORMS ST-246 AND METHODS OF PREPARATION</i> Polymorphic forms I, II, IV, VI processes for their preparation, methods of treatment, pharmaceutical compositions, and dosage unit forms	US	9,339,466	Issued
		US	14,959,180	Pending
Tecovirimat (ST-246, TPOXX) Family III	<i>ST-246 LIQUID FORMULATIONS</i> Liquid formulations comprising cyclodextrin, methods of treatment, process for making, unit dosage forms	US	9,233,097	Issued
		US	14,955,674	Pending
Tecovirimat (ST-246, TPOXX) Family IV	<i>METHODS OF PREPARING TECOVIRIMAT</i> Methods of preparation	US	14,420,728	Pending

Compound Series	Title/Description	Country	Application/Patent No.	Status
Tecovirimat (ST-246, TPOXX) Family V	<i>AMORPHOUS TECOVIRIMAT PREPARATION</i> Amorphous form	US	14/903,083	Pending
Tecovirimat (ST-246, TPOXX) Family VI	<i>REHYDRATION OF MICRONIZATION TECOVIRIMAT MONOHYDRATE</i> Rehydration/Micronization	US	15/027,557	Pending
Tecovirimat (ST-246, TPOXX) Family VII	<i>ST-246 (TECOVIRIMAT MONOHYDRATE) SUSPENSION FORMULATIONS</i> Suspension formulations	US Provisional	62/295,710	Pending
ST-981/ Dengue	<i>ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION</i> Pharmaceutical compositions and methods of treating dengue infection	US	8,518,960	Issued
		US	9,353,061	Issued
		US	15/148,241	Pending
ST-610/ Dengue	<i>SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION</i> Pharmaceutical compositions and methods of treating dengue infection	US	9,029,376	Issued
		US	14/673,102	Pending
ST-148/ Dengue	<i>THIENOPYRIDINE DERIVATIVES FOR THE</i>	US	9,301,949	Issued
		US	15/017,748	Pending

Compound Series	Title/Description	Country	Application/ Patent No.	Status
	<i>TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS</i> Pharmaceutical compositions and methods of treating dengue infection, intermediates and compounds	US	13/708,224	Pending
ST-659/ Dengue	<i>TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTION</i> Pharmaceutical compositions , methods of treating dengue infection and compounds	US	8,993,604	Issued
		US	14/616,187	Pending
ST-669/ Broad- spectrum	<i>INHIBITORS AND METHODS OF INHIBITING BACTERIAL AND CATEGORY A AND B VIRAL PATHOGENS</i> Pharmaceutical compositions for use in treating a viral or bacterial infection and compounds, and stabilized aqueous nanosuspensions and methods of a broad spectrum anti-virals	US	9,233,087	Issued
		US	14/955,697	Pending
Ebola	<i>SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF EBOLA VIRUS</i> Pharmaceutical composition and a method of treatment	US Provisional	62/316,779	Pending

Trademarks

Trademark	Country	Class	Application/ Registration No.	Status	Registration Date
SIGA	US	5	3729965	Registered	12/22/2009
	US	42	3703521	Registered	10/27/2009
SIGA+Design	US	5	3723743	Registered	12/8/2009
	US	42	3719987	Registered	12/1/2009
Human BioArmor	US	42	3703520	Registered	10/27/2009
ST-246	US	5	3415362	Registered	4/22/2008
ARESTVYR	US	5	4,597,614	Registered	9/2/2014
TPOXX	US	5	5046109	Registered	9/20/16